Education
About Us
Working with TipRanks
Follow Us
Shionogi & Co Ltd (DE:SH0)
FRANKFURT:SH0
Earnings Data
Report Date
Jul 28, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.25Last Year’s EPS
0.22Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 1.43%
|Next Earnings Date:Jul 28, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in the HIV and overseas business segments, with significant advancements in product launches and expansion. However, this was tempered by declines in overall sales revenue, increased costs, and the dissolution of a key joint venture in China.Company Guidance
In the third quarter of fiscal year 2024, Shionogi & Co., Ltd. reported a sales revenue of JPY333.6 billion, a slight decrease of JPY3.2 billion year-on-year, primarily due to a one-time payment of JPY25 billion recorded in the previous year. However, excluding this payment, revenue increased by JPY21.8 billion, driven by a significant growth in royalty income and overseas business, notably the HIV franchise, which grew by JPY12.3 billion. Operating profit also saw an increase of JPY15.5 billion when excluding the one-time payment. Profit before tax reached JPY155.9 billion, with profit attributable to owners of the parent at JPY133.8 billion, marking an increase of JPY6.6 billion year-on-year. The company highlighted the stabilization of its domestic infectious disease business and expressed optimism in achieving the full-year forecast, bolstered by the success of its COVID-19 and influenza treatments, Xofluza and Xocova, as well as the launch of new products like QUVIVIQ. The yen's depreciation contributed to exchange gains, further supporting financial outcomes. Additionally, Shionogi emphasized its commitment to cost management and strategic R&D investments to sustain growth across its business segments.Strong Growth in HIV Business
The HIV franchise grew significantly, with royalty income increasing by JPY12.3 billion compared to the third quarter of last year. The LA formulation treatment increased by 43.4% year-on-year.
Overseas Business Expansion
Cefiderocol sales increased by 39.6% in the United States and 25.6% in Europe year-on-year. The number of countries where it is sold increased to 25.
Stable Domestic Infectious Disease Business
Sales of influenza and COVID-19 treatment drugs like Xofluza expanded in Q3 due to the spread of influenza in December.
Launch of New Products
The insomnia treatment drug, QUVIVIQ, was launched on December 19, marking a new sales record.
DE:SH0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:SH0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | €14.00 | €13.20 | -5.71% |
Jan 31, 2025 | €13.30 | €13.40 | +0.74% |
Oct 28, 2024 | €11.82 | €11.72 | -0.84% |
Jul 29, 2024 | €12.89 | €12.51 | -3.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Shionogi & Co Ltd (DE:SH0) report earnings?
Shionogi & Co Ltd (DE:SH0) is schdueled to report earning on Jul 28, 2025, TBA Not Confirmed.
What is Shionogi & Co Ltd (DE:SH0) earnings time?
Shionogi & Co Ltd (DE:SH0) earnings time is at Jul 28, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Shionogi & Co Ltd stock?
The P/E ratio of Shionogi & Co is N/A.
What is DE:SH0 EPS forecast?
DE:SH0 EPS forecast for the fiscal quarter 2025 (Q1) is 0.25.